Skip to content

A Clinical Cohort Study on the Intervention of Sarcopenia with Knee Osteoarthritis Using Integrated Traditional Chinese and Western Medicine Therapy

A Clinical Cohort Study on the Intervention of Sarcopenia with Knee Osteoarthritis Using Integrated Traditional Chinese and Western Medicine Therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026000689
Enrollment
Unknown
Registered
2026-03-23
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia with Knee Osteoarthritis

Interventions

Conventional Western medicine treatment group:Conventional Western medicine treatment group
Chinese herbal medicine exposure group:Jianpi Qiangji Granules

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) Meet the diagnostic criteria for sarcopenia; 2) Age: 50–85 years; 3) Meet the diagnostic criteria for knee osteoarthritis; 4) Baseline nutritional status: Mini Nutritional Assessment Short-Form (MNA-SF) score=8 (indicating no risk of malnutrition or low risk of malnutrition); 5) Voluntarily participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Individuals meeting any of the following criteria will not be included in this trial:Severe malnutrition (defined as: MNA-SF score = 7, or as comprehensively assessed by a clinician/nutritionist); Patients with advanced chronic consumptive diseases, such as advanced malignant tumors, chronic obstructive pulmonary disease (COPD), severe chronic kidney disease (eGFR<30 and above), severe diabetes, or other diseases or physiological conditions that could affect muscle mass; Patients with acute loss of mobility, such as reduced mobility due to various fractures, especially after hip fracture; Severely obese individuals; Patients with neuromuscular diseases, such as Parkinson's disease; Individuals positive for Hepatitis B surface antigen, Hepatitis C antibody, or HIV antibody; Patients with mental illness; Individuals with hearing or visual impairments that interfere with communication or daily activities; Individuals with cognitive impairment; Regular use of medications potentially used to treat sarcopenia or tuina therapy within the 3 months prior to enrollment, such as calcium supplements, vitamin D and its analogs (e.g., calcitriol), androgens (testosterone, dehydrotestosterone, dihydrotestosterone, etc.), growth hormone (insulin-like growth factor, etc.); History of drug or alcohol abuse within the past year; Any subject judged by the investigator as having a reduced likelihood of enrollment (e.g., frail, etc.), a tendency towards non-compliance during the study period, or other conditions that complicate enrollment.

Design outcomes

Primary

MeasureTime frame
Calf circumference change value;

Secondary

MeasureTime frame
Muscle strength;Pain ;Physical fitness;Screening and Nutrition;Scales and Quality of Life;Related to Traditional Chinese Medicine;Imaging (or Radiology);Body composition;

Countries

China

Contacts

Public ContactFang Min

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

18939061729@163.com18939061729

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026